BIOLOG-ID/XERYS
Biolog-id, a global leader in the traceability and management of sensitive health products (red blood cells, plasma, platelets and chemotherapy preparations), is announcing a campaign to raise 30 million euros from Xerys Funds.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005064/en/
With this campaign, Biolog-id aims to exceed €200 M in turnover by 2023 and to join the clan of French unicorns — unlisted companies worth more than a billion dollars.
“We are banking on a hyper-growth strategy, announced Biolog-id’s President and Founder, Jean-Claude Mongrenier. The funds gathered will enable us to accelerate the company’s international development through its main subsidiaries — North America, Middle East and Asia — and to extend the scope of action to other regions, in particular China. The market potential that Biolog-id hopes to exploit is currently valued by experts at nearly 4 billion dollars. It should increase considerably due to strong demand from emerging countries and population ageing and growth. This additional capital should enable us to offer even greater value to our clients, both in France and abroad, by providing our solution to as many healthcare establishments as possible.”
A start-up valued at 150 million euros
This investment, made by Xerys funds, shows recognition for Biolog-id’s long-term strategic vision and the disruptive model of the Biolog-connect® solution it has developed. Today, the company is valued at 150 million euros by the strategy consulting firm Roland Berger to increase to over a billion in 2023, given its prospects for development and future results.
“Biolog-id is a future French unicorn in which we have already invested 50 million euros,” reveals Jacques Simonnet, Xerys Founder and President. “We have supported this company since it was founded in 2009. We take great pride in taking part in this new operation, which aims to multiply the company’s growth and strengthen its leading position in the traceability and management of sensitive health products. I would like to thank the Chairman for his trust and congratulate the teams for their achievement.”
How the Biolog-connect® solution works
Biolog-connect® is an IoT (internet of things) connected solution based on RFID (Radio Frequency Identification) technology. Biolog-connect® technology tells us the product’s location, temperature, storage conditions, history and characteristics in real time. Access to this essential data enables us to completely eliminate administration errors by ensuring that the right product is administered to the right patient and to check the product’s quality by guaranteeing its transport and storage conditions. The solution also enables us to make savings (ROI in less than 18 months) by improving product management, strongly reducing losses and improving the product’s journey to the patient.
About Biolog-id
Biolog-id has designed a patented smart solution to manage the transfusion chain from the donor to the receiver. Biolog-id operates in North America, Europe, the Middle East, India and the Asia-Pacific region, and has more than 100 employees worldwide. Staff numbers should double in the next three years. The Biolog-connect® solution is protected by more than 100 international patents.
Biolog-id is owned by its founder and the Xerys Funds. www.biolog-id.com
About Xerys
Xerys Gestion is a portfolio management company specialising in private equity, which places the enterprise vision at the heart of its investment philosophy, so as to support the management of its portfolio companies in all the steps of their growth, from venture capital to maturity. Xerys Funds invest between €10 M and €60 M in innovative companies in the healthcare, sustainable development or connected technologies sectors. www.xerys.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005064/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing9.6.2025 07:00:00 CEST | Press release
Azafaros, a clinical-stage biotechnology company developing novel therapies for rare lysosomal storage disorders (LSDs), today announced that it will present at the 2025 BIO International Convention taking place in Boston, USA, from 16-19 June. The company’s presentation is scheduled for Monday, June 16 at 16:45 ET in Room 153B. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). This announcement follows Azafaros’ recently completed and oversubscribed €132 million Series B financing round, which will support advancing nizubaglustat into pivotal clinical development. The company is on track to initiate two Phase 3 trials in GM1/GM2 gangliosidoses and NPC in 2025. Earlier this year, Azafaros reported positive topline results from its ongoing Phase 2 study evaluating n
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 22:32:00 CEST | Press release
Successful Transaction Marks Another Milestone in A-CAP’s Soccer Club Portfolio Strategy Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 20:00:00 CEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom